Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Surein Arulananda^{1

2

3}, Megan O'Brien¹, Marco Evangelista¹, Tiffany J Harris¹, Nikita S Steinohrt¹, Laura J Jenkins^{1

2}, Marzena Walkiewicz¹, Robert J J O'Donoghue^{1

4}, Ashleigh R Poh^{1

2}, Bibhusal Thapa¹, David S Williams^{1

2

5

6}, Trishe Leong^{3

5

6}, John M Mariadason^{1

2}, Xia Li⁷, Jonathan Cebon^{1

2

3}, Erinna F Lee^{8

9

10}, Thomas John^{11

12

13

14}, W Douglas Fairlie^{15

16

17}

Affiliations

¹ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
² School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia.
³ Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.
⁴ Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, VIC, Australia.
⁵ Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
⁶ Department of Pathology, Austin Health, Heidelberg, VIC, Australia.
⁷ Department of Mathematics and Statistics, La Trobe University, Bundoora, VIC, Australia.
⁸ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. Erinna.Lee@latrobe.edu.au.
⁹ School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. Erinna.Lee@latrobe.edu.au.
¹⁰ Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia. Erinna.Lee@latrobe.edu.au.
¹¹ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. tom.john@petermac.org.
¹² School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. tom.john@petermac.org.
¹³ Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia. tom.john@petermac.org.
¹⁴ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. tom.john@petermac.org.
¹⁵ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. doug.fairlie@onjcri.org.au.
¹⁶ School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. doug.fairlie@onjcri.org.au.
¹⁷ Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia. doug.fairlie@onjcri.org.au.

PMID: 34131107
PMCID: PMC8206255
DOI: 10.1038/s41420-020-00388-7

Published Erratum

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Surein Arulananda et al. Cell Death Discov. 2021.

. 2021 Jun 15;7(1):146.

doi: 10.1038/s41420-020-00388-7.

Authors

Affiliations

¹ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
² School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia.
³ Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.
⁴ Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, VIC, Australia.
⁵ Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
⁶ Department of Pathology, Austin Health, Heidelberg, VIC, Australia.
⁷ Department of Mathematics and Statistics, La Trobe University, Bundoora, VIC, Australia.
⁸ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. Erinna.Lee@latrobe.edu.au.
⁹ School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. Erinna.Lee@latrobe.edu.au.
¹⁰ Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia. Erinna.Lee@latrobe.edu.au.
¹¹ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. tom.john@petermac.org.
¹² School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. tom.john@petermac.org.
¹³ Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia. tom.john@petermac.org.
¹⁴ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. tom.john@petermac.org.
¹⁵ Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia. doug.fairlie@onjcri.org.au.
¹⁶ School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia. doug.fairlie@onjcri.org.au.
¹⁷ Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia. doug.fairlie@onjcri.org.au.

PMID: 34131107
PMCID: PMC8206255
DOI: 10.1038/s41420-020-00388-7

No abstract available

PubMed Disclaimer

Erratum for

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. Arulananda S, et al. Cell Death Discov. 2020 Oct 31;6(1):114. doi: 10.1038/s41420-020-00348-1. Cell Death Discov. 2020. PMID: 33298868 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Affiliations

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials